AMPH Q4 2022 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$135M+11.7% YoY

Gross Profit

$71M52.7% margin

Operating Income

$38M28.0% margin

Net Income

$34M25.1% margin

EPS (Diluted)

$0.66

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$9M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$742M

Total Liabilities

$213M

Stockholders' Equity

$529M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$135M	$121M	+11.7%
Gross Profit	$71M	$56M	+26.6%
Operating Income	$38M	$24M	+56.0%
Net Income	$34M	$20M	+71.6%

Revenue Segments

Research and development services

$2M100%

Geographic Segments

UNITED STATES

$131M97%

CHINA

$2M2%

FRANCE

$2M1%